

2025-26 Financial statements

Cystic Fibrosis Canada is fully committed to transparency and accountability of financial information. We remain in a favourable financial position as we continue to strategically invest generous donor dollars into vital cystic fibrosis research and care, to ensure donations achieve the greatest impact.

Statement of Operations

(in thousands of dollars)

Year Ended January 31, 2026, with comparative information for 2025

Revenue	2026	2025
Community events	\$ 6,405	\$ 6,209
Annual giving	1,863	1,826
Leadership giving	1,373	1,267
Kin Canada	352	548
Corporate giving	710	929
Other	1,176	1,358
Bequests	3,363	2,347
Total	\$ 15,242	\$ 14,484
Less direct fundraising costs	3,185	3,223
Net fundraising revenue	12,057	11,261
Expenses	2026	2025
Program		
Research	\$ 4,157	\$ 4,069
Healthcare	1,331	1,312
Community engagement	1,322	1,747
Advocacy	511	534
Total	\$ 7,321	\$ 7,662
Other		
Administration	1,960	1,956
Fundraising	1,944	1,560
Total	\$ 3,904	\$ 3,516
Excess (deficiency) of revenue over expenses before the undernoted	832	83
Investment Income (Loss)	2026	2025
Realized gains on investments	\$ 237	\$ 361
Change in unrealized loss on investments	(60)	126
Total	\$ 177	\$ 487
Excess of revenue over expenses	1,009	570

Statement of Financial Position

(in thousands of dollars)

Year Ended January 31, 2026, with comparative information for 2025

Assets	2026	2025
Current Assets		
Cash and equivalents	\$ 10,460	\$ 8,433
Short-term investments	1,263	1,337
Receivables and other assets	618	955
Total	\$ 12,341	\$ 10,725
Contributions receivable	185	182
Long-term investments	4,801	4,694
Capital assets	596	612
Total	\$ 17,923	\$ 16,213
Liabilities and Net Assets	2026	2025
Current Liabilities		
Accounts payable and accrued liabilities	\$ 892	\$ 511
Deferred revenue	1,097	712
Total	\$ 1,989	\$ 1,223
Long-term liabilities	733	798
Net Assets		
Endowment	\$ 94	\$ 94
Internally restricted for research and healthcare	2,453	2,704
Invested in capital assets	256	230
Internally reserved for strategic impact fund	2,509	1,500
Unrestricted	9,889	9,664
Total	17,923	\$ 16,213

Statement of Changes in Net Assets


(in thousands of dollars)

Year ended January 31, 2026, with comparative information for 2025

	Endow- ment	Internally restricted for research and clinics	Invest in capital assets	Internally reserved for strategic impact fund	Unrestricted	2026 Total	2025 Total
Net assets, beginning of year	\$ 94	\$ 2,704	\$ 230	\$ 1,500	\$ 9,664	\$ 14,192	\$ 13,622
Excess of revenue over expenses			(52)		\$ 1,061	\$ 1,009	\$ 570
Investment in capital assets			\$ 78		(78)	-	-
Transfer between funds		(251)		\$ 1,009	(758)	-	-
Net assets, end of year	\$ 94	\$ 2,453	\$ 256	\$ 2,509	\$ 9,889	\$ 15,201	\$ 14,192


Statement of Fundraising Revenue

(Net of direct fundraising costs)



Note: Fundraising revenue excludes realized and unrealized gains/losses on investments.

After 65 years,



Complete audited financial statements are available on our website at cysticfibrosis.ca.



We are proud to be accredited by Imagine Canada's Standards Program, recognizing our commitment to transparency, accountability, and strong governance.